Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | PPARD | Q03181 | 1/20 | 0.42 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.42 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.41 |
| ▸ | GMNN | O75496 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | THPO | P40225 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10808756 | 1.00 | LMNA (0.65) | LMNAALDH1A1GPR84FFAR1MAPT | |
| SCHEMBL1278377 | 0.98 | LMNA (0.61) | LMNAALDH1A1GPR84FFAR1MAPT | |
| SCHEMBL13678853 | 0.91 | LMNA (0.59) | LMNAALDH1A1GPR84FFAR1MAPT | |
| SCHEMBL5014419 | 0.90 | LMNA (0.54) | LMNAGPR84FFAR1MAPTLCK | |
| SCHEMBL17676315 | 0.90 | LMNA (0.54) | LMNAGPR84FFAR1MAPTLCK | |
| SCHEMBL17676311 | 0.90 | LMNA (0.54) | LMNAGPR84FFAR1MAPTLCK | |
| SCHEMBL15347870 | 0.90 | LMNA (0.54) | LMNAGPR84FFAR1MAPTLCK | |
| SCHEMBL13938058 | 0.90 | LMNA (0.54) | LMNAGPR84FFAR1MAPTLCK | |
| SCHEMBL13678851 | 0.89 | LMNA (0.57) | LMNAALDH1A1GPR84FFAR1MAPT | |
| SCHEMBL17676325 | 0.88 | LMNA (0.52) | LMNAGPR84FFAR1MAPTLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1207285-C | Method of extracting Shishanjianjia from Chinese herbal medicine multi-layer tower | HENAN JOYLINE & JOYSUN PHARMAC (CN) | 2005-06-22 | — | — | CN | claimed |
| CN-1448390-A | Method of extracting Shishanjianjia from Chinese herbal medicine multi-layer tower | HENAN ZHULIN ZHONGSHENG PHARMA (CN) | 2003-10-15 | — | — | CN | claimed |
| EP-4361617-A1 | METHOD FOR PREPARING SAMPLES FOR SPECTROMETRIC ANALYSIS BY X-RAY FLUORESCENCE | Cogne Acciai Speciali S.p.A. (IT) | 2024-05-01 | — | — | EP | disclosed |
| US-20140127160-A1 | TREATMENT OF HEPATITIS C VIRUS WITH TELAPREVIR (VX-950) IN PATIENTS NON-RESPONSIVE TO TREATMENT WITH PEGYLATED INTERFERON-ALPHA 2A/2B AND RIBAVIRIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-05-08 | — | — | US | disclosed |
| US-8664273-B2 | Treatment of hepatitis C virus with telaprevir (VX-950) in patients non-responsive to treatment with pegylated interferon-alpha 2A/2B and ribavirin | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-03-04 | — | — | US | disclosed |
| US-20140056847-A1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-02-27 | — | — | US | disclosed |
| US-20130177531-A1 | Inhibitors of Serine Proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-11 | — | — | US | disclosed |
| EP-1910341-B1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMA (US) | 2013-01-02 | — | — | EP | disclosed |
| US-20120045415-A1 | TREATMENT OF HEPATITIS C VIRUS WITH TELAPREVIR (VX-950) IN PATIENTS NON-RESPONSIVE TO TREATMENT WITH PEGYLATED INTERFERON-ALPHA 2A/2B AND RIBAVIRIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-23 | — | — | US | disclosed |
| EP-2402331-A1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-04 | — | — | EP | disclosed |
| US-20110171175-A1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-14 | — | — | US | disclosed |
| WO-2009072002-A2 | BISPHENOLS IN CANCER THERAPY | UNIVERSITY OF MANITOBA (US) | 2009-06-11 | — | — | WO | disclosed |
| CN-101314555-A | Method for extracting lycopene from photosynthetic bacteria cell | UNIV BEIJING SCIENCE & TECH (CN) | 2008-12-03 | — | — | CN | disclosed |
| US-20070105781-A1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-05-10 | — | — | US | disclosed |
| CN-1207285-C | Method of extracting Shishanjianjia from Chinese herbal medicine multi-layer tower | HENAN JOYLINE & JOYSUN PHARMAC (CN) | 2005-06-22 | — | — | CN | disclosed |
| CN-1448390-A | Method of extracting Shishanjianjia from Chinese herbal medicine multi-layer tower | HENAN ZHULIN ZHONGSHENG PHARMA (CN) | 2003-10-15 | — | — | CN | disclosed |
| US-20030180435-A1 | Separation of carotenoids from fruits and vegetables | HER MAJESTY THE QUEEN IN RIGHT OF CANADA AS REPRESENTED BY THE MINISTER OF AGRICULTURE AND AGRI-FOOD (CA) | 2003-09-25 | — | — | US | disclosed |
| WO-2001079355-A1 | SEPARATION OF CAROTENOIDS FROM FRUITS AND VEGETABLES | HER MAJESTY THE QUEEN IN RIGHT OF CANADA AS REPRESENTED BY THE MINISTER OF AGRICULTURE AND AGRI-FOOD (CA) | 2001-10-25 | — | — | WO | disclosed |
| US-4937246-A | ABSORBED EASILY FROM INTESTINES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1990-06-26 | — | — | US | disclosed |
| EP-0318235-A2 | PAF antagonist, 1,4-disubstituted piperazine compounds and production thereof | Takeda Chemical Industries, Ltd. (JP) | 1989-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110171175-A1 | INHIBITORS OF SERINE PROTEASES | PRSS1, SERPINB1, PRSS3 | LMNA 1400/4885ALDH1A1 1984/4885GPR84 4221/4885 |
| US-20140056847-A1 | INHIBITORS OF SERINE PROTEASES | PRSS1, SERPINB1, PRSS3 | LMNA 1400/4885ALDH1A1 1984/4885GPR84 4221/4885 |
| US-20130177531-A1 | Inhibitors of Serine Proteases | PRSS1, SERPINB1, PRSS3 | LMNA 1400/4885ALDH1A1 1984/4885GPR84 4221/4885 |
| US-20120045415-A1 | TREATMENT OF HEPATITIS C VIRUS WITH TELAPREVIR (VX-950) IN PATIENTS NON-RESPONSIVE TO TREATMENT WITH PEGYLATED INTERFERON-ALPHA 2A/2B AND RIBAVIRIN | IFNAR1, IFNG, EIF2AK2 | LMNA 3075/4885ALDH1A1 2573/4885GPR84 2046/4885 |
| US-20070105781-A1 | Inhibitors of serine proteases | PRSS1, SERPINB1, PRSS3 | LMNA 1456/4885ALDH1A1 2154/4885GPR84 4224/4885 |
| US-20140127160-A1 | TREATMENT OF HEPATITIS C VIRUS WITH TELAPREVIR (VX-950) IN PATIENTS NON-RESPONSIVE TO TREATMENT WITH PEGYLATED INTERFERON-ALPHA 2A/2B AND RIBAVIRIN | IFNAR1, IFNG, EIF2AK2 | LMNA 3075/4885ALDH1A1 2573/4885GPR84 2046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.